TL;DR: Aetna, a CVS Health company, modified CPB 0761 covering certolizumab pegol (Cimzia) billing, effective March 5, 2026. Here's what billing teams need to do before claims hit the queue.
Aetna's updated Cimzia coverage policy adds a new covered indication — immune checkpoint inhibitor-related toxicity — and tightens the step therapy and biomarker documentation requirements for rheumatoid arthritis. The primary billing code is HCPCS J0717 (injection, certolizumab pegol, 1 mg), and supporting diagnostic codes include CPT 86200 (anti-CCP), 86430–86431 (rheumatoid factor), 86140–86141 (CRP), and 85651–85652 (ESR). If your practice bills Cimzia under CPB 0761 Aetna's commercial plans, this update changes what documentation you need at the point of prior authorization.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Certolizumab Pegol (Cimzia) — CPB 0761 |
| Policy Code | CPB 0761 |
| Change Type | Modified |
| Effective Date | March 5, 2026 |
| Impact Level | High |
| Specialties Affected | Rheumatology, Dermatology, Gastroenterology, Oncology, Hematology |
| Key Action | Update prior authorization packets to include biomarker test results (CPT 86200, 86430, 86431, 86140, 86141) and step therapy documentation before submitting Cimzia requests |
Aetna Certolizumab Pegol Coverage Criteria and Medical Necessity Requirements 2026
Aetna's Cimzia coverage policy requires prior authorization for every indication. Call (866) 752-7021 or fax (888) 267-3277 to initiate precertification. There is no path around this step — missing it means a clean claim denial before Aetna even looks at clinical criteria.
The prescriber specialty requirement is firm. A rheumatologist must prescribe or consult for RA, polyarticular juvenile idiopathic arthritis (pJIA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). A rheumatologist or dermatologist can prescribe for psoriatic arthritis. A gastroenterologist must be in the loop for Crohn's disease. A dermatologist handles plaque psoriasis. For the newly added immune checkpoint inhibitor-related toxicity indication, an oncologist, hematologist, or rheumatologist qualifies. Document the prescriber's specialty in the prior auth packet — Aetna will check it.
Rheumatoid Arthritis: The Step Therapy Maze
The RA criteria are the most complex in this policy, and they create real claim denial risk if your documentation is thin.
Aetna considers Cimzia medically necessary for RA under two paths. Path one is simple: the member received a biologic or targeted synthetic DMARD (for example, Rinvoq or Xeljanz) for moderately to severely active RA within the past 120 days. Document the prior biologic. Done.
Path two is where most practices run into trouble. The member must have biomarker testing on file AND documented step therapy failure. For biomarkers, Aetna accepts two scenarios. Either the member tested positive for rheumatoid factor (CPT 86430 or 86431) or anti-CCP (CPT 86200) — a positive on either satisfies the requirement. Or the member was tested for all three: RF, anti-CCP, and CRP (CPT 86140 or 86141) or ESR (CPT 85651 or 85652). A negative panel across all three still satisfies the testing requirement, but you must show all tests were run.
The step therapy requirement is a tiered methotrexate trial. The member must have failed — or been unable to tolerate — a 3-month trial of MTX at a maximum titrated dose of at least 15 mg per week. Billing codes for MTX appear in the policy (J8610, J8611, J8612, J9250, J9260) as supporting evidence codes. If the member stopped MTX, they need documented inadequate response to another conventional synthetic DMARD — leflunomide, hydroxychloroquine, or sulfasalazine — alone or in combination after a 3-month trial.
There are outs for contraindications and intolerable adverse events, but every one of them requires documentation. "Patient couldn't tolerate" is not enough. Your rheumatologist needs to chart the specific adverse event or the contraindication reason.
Psoriatic Arthritis
For psoriatic arthritis, medical necessity requires a documented inadequate response to or intolerance of at least one conventional synthetic DMARD — typically MTX, leflunomide, or sulfasalazine. The prescriber must be a rheumatologist or dermatologist. ICD-10 codes L40.50 through L40.59 (psoriatic arthropathy) apply here.
Crohn's Disease
The gastroenterologist requirement is absolute for Crohn's disease. Aetna looks for documented moderate to severe disease activity and prior conventional therapy failure. ICD-10 codes K50.00 through K50.919 apply.
Plaque Psoriasis
A dermatologist must prescribe. Aetna requires documented moderate to severe plaque psoriasis (body surface area or DLQI criteria), prior phototherapy or conventional systemic therapy trial, and clinical photography or measurement. ICD-10 codes L40.0 through L40.8 apply.
Immune Checkpoint Inhibitor-Related Toxicity — The New Indication
This is the most notable addition in the March 2026 update. Aetna now covers Cimzia for immune checkpoint inhibitor-related inflammatory toxicity. This applies to oncology and hematology patients on checkpoint inhibitors (pembrolizumab, nivolumab, and similar agents) who develop inflammatory conditions — including arthritis, colitis, and other immune-mediated complications — as a treatment side effect. The prescriber can be an oncologist, hematologist, or rheumatologist.
This matters for oncology billing teams who may not have Cimzia in their charge capture at all. Add J0717 to your oncology drug formulary now. And confirm your prior auth workflow covers oncology-initiated requests — because your rheumatology team's PA process probably won't flag these cases automatically.
Aetna Certolizumab Pegol Exclusions and Non-Covered Indications
Aetna does not cover Cimzia for indications outside the approved list. The policy lists several off-label uses as experimental, investigational, or unproven. These include use in conditions where biologic monotherapy is not supported by guideline-level evidence.
Sarcoidosis (D86.0 through D86.9) appears in the ICD-10 code set associated with this policy, as do codes for uveitis (H20.9), severe persistent asthma (J45.50 through J45.52), and microscopic colitis (K52.838, K52.839). The presence of these codes in the policy does not mean Aetna covers Cimzia for these conditions automatically. They appear in the "other codes related to the CPB" group, which Aetna uses to track related diagnoses for review purposes.
If you're billing Cimzia for one of these diagnoses without an approved indication, expect a denial. Talk to your compliance officer before submitting — the financial exposure on a biologics claim is significant, and the appeal path for experimental designations is long.
Coverage Indications at a Glance
| Indication | Status | Key Codes | Notes |
|---|---|---|---|
| Rheumatoid arthritis (moderate to severe) | Covered | J0717, 86200, 86430, 86431, 86140, 86141, 85651, 85652 | Biomarker testing + MTX step therapy required; prior auth mandatory |
| Polyarticular juvenile idiopathic arthritis | Covered | J0717 | Rheumatologist must prescribe; prior auth mandatory |
| Ankylosing spondylitis | Covered | J0717 | Rheumatologist must prescribe; conventional DMARD failure required |
| Non-radiographic axial spondyloarthritis | Covered | J0717 | Rheumatologist must prescribe; imaging evidence required |
| Psoriatic arthritis | Covered | J0717, L40.50–L40.59 | Rheumatologist or dermatologist; DMARD failure required |
| Crohn's disease | Covered | J0717, K50.00–K50.919 | Gastroenterologist required; moderate to severe disease |
| Plaque psoriasis (moderate to severe) | Covered | J0717, L40.0–L40.8 | Dermatologist required; prior phototherapy or systemic therapy trial |
| Immune checkpoint inhibitor-related toxicity | Covered (NEW) | J0717 | Oncologist, hematologist, or rheumatologist; new as of March 2026 |
| Sarcoidosis | Not covered / Experimental | D86.0–D86.9 | Listed as related diagnosis only; no coverage criteria in policy |
| Severe persistent asthma | Not covered / Experimental | J45.50–J45.52 | Listed as related diagnosis only |
| Uveitis | Not covered / Experimental | H20.9 | Listed as related diagnosis only |
| Microscopic colitis | Not covered / Experimental | K52.838, K52.839 | Listed as related diagnosis only |
Aetna Cimzia Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Add J0717 to your prior auth workflow before March 5, 2026. Every Cimzia claim under Aetna commercial plans requires precertification. Call (866) 752-7021 or fax (888) 267-3277. There is no exception. Missing prior auth is the fastest path to a clean denial with no clinical review. |
| 2 | Build a biomarker checklist into your RA prior auth packet. For every new RA patient, collect CPT 86430 or 86431 (RF), CPT 86200 (anti-CCP), and CPT 86140 or 86141 (CRP) or 85651/85652 (ESR) before submitting. A missing lab result — not just a negative result — will get the request kicked back. |
| 3 | Document MTX step therapy with dates and doses. Aetna requires a 3-month trial at a maximum titrated dose of at least 15 mg per week. Vague chart notes won't pass clinical review. Your rheumatology notes need to show the specific dose, duration, and reason for stopping or failing. Pull J8610, J8611, J8612, J9250, or J9260 billing history as supporting documentation if the patient was managed at your practice. |
| 4 | Create an oncology-to-rheumatology PA pathway for checkpoint inhibitor toxicity. This new indication means your oncology team may initiate a Cimzia request. Your prior auth process needs a handoff protocol. Confirm that billing staff know J0717 is billable in oncology settings and that the prescriber specialty (oncologist, hematologist, or rheumatologist) is documented in the PA request. |
| 5 | Verify prescriber specialty documentation for every indication. Aetna checks it. A PA request for plaque psoriasis initiated by a rheumatologist — without dermatologist consultation documented — will not meet the coverage policy. Build specialty verification into your intake workflow, not your denial management workflow. |
| 6 | Audit TB screening documentation. The policy includes CPT 86480, 86481 (TB interferon gamma tests), and 86580 (TB skin test) as related codes. Aetna expects active TB to be ruled out before biologic initiation. Your prior auth packet should include TB screening results — a missing TB test is a fast denial for a biologic PA. |
| 7 | Review reimbursement rates for J0717 under your Aetna contracts. Certolizumab pegol billing reimbursement can vary significantly between commercial plan designs. Confirm your contracted rate for J0717 and whether Aetna applies a specialty pharmacy carve-out. If the drug is dispensed through a specialty pharmacy rather than your in-office supply, the billing route — and the reimbursement — changes. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Certolizumab Pegol Under CPB 0761
Covered HCPCS Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J0717 | HCPCS | Injection, certolizumab pegol, 1 mg |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| D86.0–D86.9 | Sarcoidosis (related diagnosis; not a covered indication) |
| H20.9 | Unspecified iridocyclitis / uveitis NOS (related diagnosis) |
| J45.50 | Severe persistent asthma, uncomplicated |
| J45.51 | Severe persistent asthma with acute exacerbation |
| J45.52 | Severe persistent asthma with status asthmaticus |
| K50.00–K50.919 | Crohn's disease (regional enteritis) — covered indication |
| K52.838 | Microscopic colitis, other (related diagnosis) |
| K52.839 | Microscopic colitis, unspecified (related diagnosis) |
| L40.0 | Psoriasis vulgaris — covered indication |
| L40.1 | Generalized pustular psoriasis — covered indication |
| L40.2 | Acrodermatitis continua — covered indication |
| L40.50–L40.59 | Psoriatic arthropathy — covered indication |
Get the Full Picture for CPT 86200
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.